92 related articles for article (PubMed ID: 6941685)
1. The New Zealand mouse as a model for the therapy of human SLE: immunomodulation of murine lupus by sex hormones and cyclophosphamide.
Papoian R; Roubinian JR; Dauphinée MJ; Talal N
Agents Actions Suppl; 1980; 7():41-5. PubMed ID: 6941685
[No Abstract] [Full Text] [Related]
2. Ongoing immunologic activity after short courses of pulse cyclophosphamide in the NZB/W murine model of systemic lupus erythematosus.
Austin HA; Patel AD; Cadena CA; Boumpas DT; Balow JE
J Rheumatol; 1997 Jan; 24(1):61-8. PubMed ID: 9002012
[TBL] [Abstract][Full Text] [Related]
3. Natural history of murine lupus. Modulation by sex hormones.
Talal N
Arthritis Rheum; 1978 Jun; 21(5 Suppl):S58-63. PubMed ID: 352366
[TBL] [Abstract][Full Text] [Related]
4. Antibodies binding polyriboadenylic acid in systemic lupus erythematosus. Immunochemical characterization and isolation by affinity chromatography.
Pillarisetty RJ; Becker MJ; Palmer DW; Talal N
Clin Exp Immunol; 1975 Dec; 22(3):419-25. PubMed ID: 1083783
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
[TBL] [Abstract][Full Text] [Related]
6. Levamisole maintains cyclophsophamide-induced remission in murine lupus erythematosus.
Zulman J; Michalski J; McCombs C; Greenspan J; Talal N
Clin Exp Immunol; 1978 Feb; 31(2):321-7. PubMed ID: 306328
[TBL] [Abstract][Full Text] [Related]
7. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
8. [Experimental approach to the pathogenesis of systemic lupus erythematosus].
Lambert PH; Creighton D; Goodman R; Bankhurst A; Mischer PA
J Urol Nephrol (Paris); 1972 Dec; 78(12):973-80. PubMed ID: 4350279
[No Abstract] [Full Text] [Related]
9. Therapeutic trials with levamisole and other agents in NZB/W mice.
Russell AS
J Rheumatol; 1976 Dec; 3(4):380-3. PubMed ID: 1088166
[TBL] [Abstract][Full Text] [Related]
10. Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA.
Qiao B; Wu J; Chu YW; Wang Y; Wang DP; Wu HS; Xiong SD
Rheumatology (Oxford); 2005 Sep; 44(9):1108-14. PubMed ID: 15840592
[TBL] [Abstract][Full Text] [Related]
11. Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice.
Hughes GC; Martin D; Zhang K; Hudkins KL; Alpers CE; Clark EA; Elkon KB
Arthritis Rheum; 2009 Jun; 60(6):1775-84. PubMed ID: 19479860
[TBL] [Abstract][Full Text] [Related]
12. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus.
Roubinian JR; Papoian R; Talal N
J Clin Invest; 1977 Jun; 59(6):1066-70. PubMed ID: 864003
[TBL] [Abstract][Full Text] [Related]
13. Effects of pulse cyclophosphamide on NZB/W disease.
Chia D; Levy L; Barnett EV; Carnes WH
Immunology; 1981 May; 43(1):57-65. PubMed ID: 6454649
[TBL] [Abstract][Full Text] [Related]
14. NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci.
Waters ST; Fu SM; Gaskin F; Deshmukh US; Sung SS; Kannapell CC; Tung KS; McEwen SB; McDuffie M
Clin Immunol; 2001 Sep; 100(3):372-83. PubMed ID: 11513551
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse.
Owen KL; Shibata T; Izui S; Walker SE
J Biol Response Mod; 1989 Aug; 8(4):366-74. PubMed ID: 2666586
[TBL] [Abstract][Full Text] [Related]
16. Acceleration of glomerulonephritis in NZB x NZW mice by early immunization with DNA and injection of bacterial lipopolysaccharide. Experimental approach to the treatment of lupus nephritis by use of the accelerated model of NZB x NZW mouse disease.
Fournie GJ; Minh MG; Mignon-Conte MA; Hass S; Lambert PH; Conte JJ
J Clin Lab Immunol; 1980 Sep; 4(2):103-6. PubMed ID: 7441709
[TBL] [Abstract][Full Text] [Related]
17. Treatment of lupus nephritis.
Pollak VE
Adv Nephrol Necker Hosp; 1976; 6():137-61. PubMed ID: 828444
[No Abstract] [Full Text] [Related]
18. Systemic lupus erythematosus--immunoregulatory therapies.
Miller ML; Steinberg AD
Clin Rheum Dis; 1983 Dec; 9(3):617-28. PubMed ID: 6360516
[No Abstract] [Full Text] [Related]
19. Sophorae radix reduces autoimmune response in NZB/w F1 systemic lupus erythematosus mouse model.
Ko E; Lee Y; Park N; Cho C; Yim YN; Kim J; Kim YS; Kim D; Shin MK; Hong MC; Bae H
Lupus; 2007; 16(5):335-41. PubMed ID: 17576735
[TBL] [Abstract][Full Text] [Related]
20. Genetic basis of murine lupus.
Santiago-Raber ML; Laporte C; Reininger L; Izui S
Autoimmun Rev; 2004 Jan; 3(1):33-9. PubMed ID: 14871647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
